This is a single-arm, open-label, multicenter study designed to evaluate the preliminary
antineoplastic activity, safety and tolerability of HA121-28 tablets administered orally in
patients with medullary thyroid cancer (MTC).
A total of approximately 30 patients with MTC will be enrolled. The patients will undergo a 3
weeks-on and 1week-off treatment scheme with HA121-28 tablets 450 mg orally once daily in the
28-day cycle until disease progression or intolerable toxic reaction, whichever occurs first.
During the administration of HA121-28 tablets, vital signs, physical examination, ECOG
performance status, hematology and chemistry test, ECG, adverse events and concomitant drugs
will be evaluated every four weeks, an additional ECG will be observed two weeks after the
first dose, calcitonin and pregnancy test will be performed every 8 weeks. CT for tumor
assessment will be performed every 8 weeks for the first year, and every 12 weeks thereafter.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.